Polomar Health Services Reports Revenue Surge to $1.53 Million in Latest Quarter

Polomar Health Services, Inc. reported significant financial improvements in its latest quarterly filing, with revenues soaring to $1.53 million for the three months ended June 30, 2026, compared to just $5,470 in the same period last year. For the first half of 2026, the company generated $2.53 million in revenue, a substantial increase from $10,011 in the prior year. This growth is attributed to the expansion of its commercial pharmacy operations and a marked increase in prescription fulfillment volume, particularly in compounded medications.

The company's cost of goods sold also rose, reflecting the increased sales activity, totaling $592,789 for the second quarter of 2026, up from $1,638 in the previous year. Despite this, Polomar achieved a gross profit of $935,916, compared to $3,832 in the same quarter of 2025, resulting in a gross margin of approximately 61.2%. Operating expenses, however, saw a mixed trend; general and administrative expenses decreased significantly by 53.1% to $261,120, while sales and marketing expenses surged to $456,419, reflecting the company's investment in expanding its market presence.

Operationally, Polomar has made strides in its strategic direction since acquiring Polomar Pharmacy in September 2024. The company is now licensed to operate in 28 states and is actively pursuing additional licenses to broaden its reach. A key development was the execution of a pharmacy services agreement with CareValidate, which has begun generating revenue through prescription fulfillment for telehealth patients. The company is also preparing to launch SlimRx™, a telehealth platform aimed at weight-loss treatment, expected to further enhance prescription volumes.

Despite these advancements, Polomar faces challenges, including an accumulated deficit of $13.53 million as of June 30, 2026, raising concerns about its ability to continue as a going concern. The company has indicated that it will need to secure additional capital and explore new business opportunities to sustain its operations. Management's outlook emphasizes the importance of increasing revenue through expanded pharmacy services and securing new business-to-business customers, while also addressing the need for improved financial performance and operational scale.

In terms of governance, the company has undergone significant changes, including the resignation of key board members and the appointment of new directors to enhance oversight. Additionally, the company has amended its equity incentive plan to adjust the annual increase in share reserves, reflecting a strategic shift in its compensation structure. As Polomar continues to navigate its growth trajectory, the focus remains on leveraging its pharmacy capabilities and expanding its market presence to drive future success.